Addex appoints Rocher as Head of Development; GABAB PAM rights regain
Oct 2, 2026, 1:12 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Leadership changes at a clinical-stage biopharma can influence execution timelines and investor confidence. Regaining rights to a key program (GABAB PAM) from Indivior directly impacts potential pipeline value and partnering/licensing options. In past biotech events, such catalysts—new leadership and revived programs—have driven short-term upside, especially when multiple assets are nearing clinical development. Risks include execution failures and funding dependencies, but the immediate licensing/regaining detail provides a concrete, price-relevant catalyst.
AI summary
What happened, with direct paths to the underlying reporting
Addex Therapeutics appointed Jean-Philippe Rocher as Head of Pharmaceutical Development, signaling a leadership-driven push to advance multiple drug candidates. Co-founder Mikhail Kalinichev is stepping down to focus on Neurosterix. The company also regains rights to its GABAB PAM program from Indivior, with several candidates ready to enter clinical development, potentially unlocking pipeline value.
Jean-Philippe Rocher named Head of Pharmaceutical Development. He returns after retirement.
Mikhail Kalinichev steps down as Head of Translational Science to focus on Neurosterix.
GABAB PAM program rights regained from Indivior; several candidates ready to start clinical development.
Rocher previously led Addex’s chemistry platform and contributed to dipraglurant advancement.
ADXN holds 20% equity in Neurosterix; invested in Stalicla.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Addex Therapeutics shares surged 39% after selecting clinical candidates. Collaboration could yield up to $330 million in milestones and royalties. Overall market declined slightl…
